PT-141 news and clinical trials

A narrative review of 76 studies on peptide use in urology and sexual medicine found that while some agents like Bremelanotide and Tesamorelin have clinical backing, many others like CJC-1295 remain unvalidated and accessible only through unregulated markets.

Researchers developed a stability-indicating RP-HPLC method to characterize bremelanotide degradation. Forced degradation studies revealed 8 degradation products, with major pathways involving deacetylation, peptide-bond hydrolysis, oxidation, and epimerization.

Scientists synthesized 14 macrocyclic peptide analogs based on MT-II, SHU-9119, and PG-901 scaffolds to target human melanocortin receptors. The novel compounds FM648 and FM636 emerged as potent, selective hMC4R antagonists, while FM635 demonstrated selective agonist activity.

New systematic review in Frontiers in medicine: Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov.

Researchers analyzed baseline data from clinical trials to quantify sexual activity among women with hypoactive sexual desire disorder. Participants engaged in sexual activity approximately 2.5 times per month despite their condition.

A review of FDA-approved drugs containing D-amino acids highlights their role in improving peptide stability and receptor selectivity. More than 20 approved drugs, including bremelanotide and etelcalcetide, utilize D-amino acids in their structure.

New review in Frontiers in aging: Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

The Journal of Clinical Psychopharmacology published a study discussing whether bremelanotide should be considered for the treatment of sexual arousal and desire disorders in men.

A review of sexual dysfunction management in breast and gynecologic cancer survivors identified pharmacological agents such as bremelanotide and flibanserin as effective treatments for low sexual desire. The findings emphasize the need for individualized, multimodal management.

Cosette Pharmaceuticals completed a Phase 4 study in 10 healthy, lactating females to evaluate if bremelanotide is secreted into breast milk after a single 1.75 mg subcutaneous dose of Vyleesi.